Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
Key Highlights
- ➤LOQTORZI revenue $14.0 million, up 25% year over year
- ➤Coherus prioritizes tagmokitug/toripalimab development in esophageal cancer
- ➤Headcount reduction of approximately 30% supports organizational right-sizing
- ➤Core cash burn expected to decline $6 million to $7 million quarterly
- ➤Second-line ESCC/EAC showed 33.3% confirmed ORR and 55.6% CBR
Expert Statements
Denny Lanfear, Chief Executive Officer of Coherus Oncology
“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization.”
Denny Lanfear, Chief Executive Officer of Coherus Oncology
“Over the next four or five quarters we will remain intensely focused on growing LOQTORZI market share in relation to chemo-only, an inferior therapeutic approach, and off-label IO, which has not demonstrated standard-of-care level of benefit for patients living with nasopharyngeal carcinoma.”
Denny Lanfear, Chief Executive Officer of Coherus Oncology
“We believe this approach can provide a path to financial self-sufficiency.”
Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology
“Esophageal cancers constitute difficult-to-treat tumors with significant unmet medical need.”
Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology
“The compelling anti-tumor activity observed in both ESCC and EAC tumors suggests that Tregs are a critical driver of resistance.”
Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology
“Importantly, we saw tagmokitug enhance PD-1’s activity, demonstrate activity in PD-L1 negative tumors, and rescue PD-1 refractory patients.”
Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology
“Our immediate next step is to align with the FDA on our plans to expand the signal observed in esophageal cancer, with an initial focus on the second-line setting.”
Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology
“This represents the fastest path to market in this underserved patient population.”
Bryan McMichael, Chief Financial Officer of Coherus Oncology
“The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model.”
Bryan McMichael, Chief Financial Officer of Coherus Oncology
“These benefits will be realized over the next two quarters, lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million, as previously guided.”
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –
– Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication –
Get started
Create a free account to read the full story.